



PALLA PHARMA

## ASX ANNOUNCEMENT

**Wednesday 22 September 2021**

### Half Year Results and Investor Update Conference Call

Palla Pharma Limited (ASX:PAL) advises that it will host an analyst and investor conference call on Thursday 30 September 2021 at 4:30pm AEST to present the Company's results for the half year ended 30 June 2021 and provide an investor update. The call will be presented by Chairman Simon Moore, Chief Executive Officer Giles Moss, and Chief Financial Officer Brendan Middleton.

An accompanying presentation will be made available via the ASX announcement platform prior to the call.

#### Conference call details

To pre-register for this conference and avoid a queue when calling, please use the following link below:

<https://sl.c-conf.com/diamondpass/10016805-wk3a06.html>

You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

If you are unable to register, then at the time of the conference you can call one of the numbers below:

- Attendee Dial-in (Australia Toll Free): **1800 954 501**
- Alternative Australia Toll Free: **1800 870 653**

This announcement has been authorised for release by the Chairman of Palla Pharma.

---

#### For more information please contact:

##### Simon Moore

Chairman  
Palla Pharma Limited  
+61 3 9301 0800

##### Adrian Mulcahy

Investor Relations  
Market Eye  
+61 438 630 422 or [ir@pallapharma.com](mailto:ir@pallapharma.com)

##### Giles Moss

CEO  
Palla Pharma Limited  
+61 3 9301 0800

##### Tristan Everett

Media Enquiries  
Market Eye  
+61 403 789 096 or [media@pallapharma.com](mailto:media@pallapharma.com)

---

#### Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

**T** +61 3 9301 0800 / **F** +61 3 9301 0899 / **W** [pallapharma.com](http://pallapharma.com) / **E** [info@pallapharma.com](mailto:info@pallapharma.com)



PALLA PHARMA

**About Palla Pharma Limited:**

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

**Palla Pharma Limited**

PO Box 2139 Melbourne, VIC 3001, Australia

**T** +61 3 9301 0800 / **F** +61 3 9301 0899 / **W** [pallapharma.com](http://pallapharma.com) / **E** [info@pallapharma.com](mailto:info@pallapharma.com)